SCHEMBL4160010

SCHEMBL4160010

CCC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO

nearest known ligand 0.58

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 1/20 0.58
LMNA P02545 2/20 0.54
L3MBTL1 Q9Y468 1/20 0.50
TDP1 Q9NUW8 1/20 0.48
USP2 O75604 1/20 0.43
SLCO1B1 Q9Y6L6 1/20 0.43
KDM4E B2RXH2 2/20 0.41
CYP2C9 P11712 1/20 0.37
TSHR P16473 1/20 0.37
TOP1 P11387 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13998446 1.00 PDE4A (0.58) PDE4ALMNAL3MBTL1TDP1USP2
SCHEMBL13998326 1.00 PDE4A (0.58) PDE4ALMNAL3MBTL1TDP1USP2
SCHEMBL8083544 1.00 PDE4A (0.58) PDE4ALMNAL3MBTL1TDP1USP2
SCHEMBL29756403 1.00 PDE4A (0.58) PDE4ALMNAL3MBTL1TDP1USP2
SCHEMBL9965102 1.00 PDE4A (0.58) PDE4ALMNAL3MBTL1TDP1USP2
SCHEMBL8095380 1.00 PDE4A (0.58) PDE4ALMNAL3MBTL1TDP1USP2
SCHEMBL343766 1.00 PDE4A (0.58) PDE4ALMNAL3MBTL1TDP1USP2
Ammonia Solution, Strong SCHEMBL28915080 0.98 PDE4A (0.56) PDE4ALMNAL3MBTL1TDP1USP2
SCHEMBL15239580 0.93 PDE4A (0.48) PDE4ALMNAL3MBTL1TDP1USP2
SCHEMBL13879019 0.93 PDE4A (0.48) PDE4ALMNAL3MBTL1TDP1USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102365025-A Conjugate-based systems for controlled drug delivery SMARTCELLS INC 2012-02-29 CN claimed
CN-122055379-A Compounds containing one or more diboronate esters and related insulin analogues 普罗托莫科技公司 2026-05-15 CN disclosed
EP-4694932-A2 COMPOUNDS CONTAINING ONE OR MORE DIBORONATES AND RELATED INSULIN ANALOGS Protomer Technologies Inc. (US) 2026-02-18 EP disclosed
US-20260021190-A1 GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A PENTA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES MERCK SHARP & DOHME LLC (US) 2026-01-22 US disclosed
US-12427187-B2 Glucose-responsive insulin conjugates MERCK SHARP & DOHME LLC (US) 2025-09-30 US disclosed
EP-4615487-A1 GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A PENTA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES Merck Sharp & Dohme LLC (US) 2025-09-17 EP disclosed
US-20250249074-A1 GLUCOSE RESPONSIVE INSULINS PROTOMER TECHNOLOGIES INC. 2025-08-07 US disclosed
EP-4525919-A1 AROMATIC BORON-CONTAINING COMPOUNDS AND RELATED INSULIN ANALOGS Protomer Technologies Inc. (US) 2025-03-26 EP disclosed
CN-119677541-A Aromatic boron-containing compounds and related insulin analogues 原聚体科技公司 2025-03-21 CN disclosed
US-12214018-B2 Glucose responsive insulins PROTOMER TECHNOLOGIES, INC. (US) 2025-02-04 US disclosed
EP-1854805-B1 Coffee-derived surfactants INTERCONTINENTAL GREAT BRANDS LLC (US) 2016-06-22 EP disclosed
US-20140065282-A1 Coffee-Derived Surfactants INTERCONTINENTAL GREAT BRANDS LLC (US) 2014-03-06 US disclosed
US-8603562-B2 Coffee-derived surfactants INTERCONTINENTAL GREAT BRANDS LLC (US) 2013-12-10 US disclosed
CN-102365025-A Conjugate-based systems for controlled drug delivery SMARTCELLS INC 2012-02-29 CN disclosed
CN-102341409-A Crystalline insulin-conjugates SMARTCELLS INC 2012-02-01 CN disclosed
US-20090252850-A1 Coffee-Derived Surfactants INTERCONTINENTAL GREAT BRANDS LLC 2009-10-08 US disclosed
EP-1854805-A2 Coffee-derived surfactants Kraft Foods Holdings, Inc. (US) 2007-11-14 EP disclosed
US-20070259084-A1 Coffee-Derived Surfactants KRAFT FOODS GLOBAL BRANDS LLC 2007-11-08 US disclosed
JP-2000273029-A HAIR COSMETICS KANEBO LTD 2000-10-03 JP disclosed
JP-2000273023-A HAIR CONDITIONING COMPOSITION KANEBO LTD 2000-10-03 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12427187-B2 Glucose-responsive insulin conjugates GPR119, IRS1, INSR PDE4A 2529/4885LMNA 4836/4885L3MBTL1 1420/4885
US-20250249074-A1 GLUCOSE RESPONSIVE INSULINS GLP1R, GPR119, IAPP PDE4A 1444/4885LMNA 4196/4885L3MBTL1 2699/4885
US-20260021190-A1 GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A PENTA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES INSR, GPR119, GLP1R PDE4A 2286/4885LMNA 4564/4885L3MBTL1 2640/4885
US-12214018-B2 Glucose responsive insulins GLP1R, GPR119, IAPP PDE4A 1411/4885LMNA 4296/4885L3MBTL1 2729/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.